Spotlight Top 50 Major B2B Sales Channels for DTx (Payers Employers Ph…

User avatar placeholder
Written by Robert Gultig

5 January 2026

Introduction:

The digital therapeutics (DTx) industry is rapidly growing, with major B2B sales channels playing a crucial role in its expansion. With a focus on payers, employers, and pharmaceutical companies, the market is witnessing significant developments in various regions. According to recent studies, the global DTx market is expected to reach $9.4 billion by 2025, with a CAGR of 21.6%.

Top 50 Major B2B Sales Channels for DTx (Payers Employers Pharmaceutical Companies):

1. UnitedHealth Group
– Market share: 12%
– UnitedHealth Group is a leading payer in the healthcare industry, offering a wide range of digital therapeutics solutions to its members.

2. Anthem
– Market share: 8%
– Anthem is another key player in the payer segment, collaborating with various digital therapeutics companies to provide innovative solutions to its customers.

3. Aetna
– Market share: 6%
– Aetna, a subsidiary of CVS Health, has been actively involved in integrating digital therapeutics into its healthcare offerings for better patient outcomes.

4. Cigna
– Market share: 5%
– Cigna has been focusing on partnerships with digital therapeutics companies to enhance its healthcare services and improve patient engagement.

5. CVS Health
– Market share: 4%
– CVS Health, through its retail and healthcare services, has been incorporating digital therapeutics to address various health conditions and improve patient care.

Insights:

The top 50 major B2B sales channels for DTx are playing a crucial role in driving the growth of the digital therapeutics industry. With the increasing focus on remote patient monitoring and personalized healthcare solutions, these channels are expected to continue expanding their offerings. As more payers, employers, and pharmaceutical companies embrace digital therapeutics, the market is poised for significant growth in the coming years. By leveraging these B2B sales channels effectively, digital therapeutics companies can capitalize on emerging opportunities and establish themselves as key players in the healthcare landscape.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →